BMJ 360:k872
As per an article published by the Canadian Health Policy Journal in April 2026, the most-favored-nation (MFN) reference-specific drug pricing policy was launched by the government, demanding brand medicines without competitors to be set at the lowest pricing strategy, with a GDP per capita of nearly 60%
The second is that initial trials indicate that the results are consistent, with other GLP-1s, people tend to lose less weight as time goes on
The good news is that you may be able to get some money back with Novo Nordisks Savings Offer reimbursement form , if you qualify
, 497 , 1117-1122, doi: Tili, E., Michaille, J
Prescription and lab work come first: Peptide therapy for muscle growth requires a medical evaluation, baseline labs including IGF-1 and fasting glucose, and ongoing monitoring